Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free IBT Stock Alerts

International Biotechnology (IBT) Competitors

International Biotechnology logo
GBX 1,095 -10.00 (-0.90%)
As of 09/24/2026 12:01 PM Eastern
Compare

IBT vs. ASHM, BNKR, BHMG, JMG, and ASL

Should you buy International Biotechnology stock or one of its competitors? International Biotechnology's main competitors and comparable companies include Ashmore Group (ASHM), The Bankers Investment Trust (BNKR), BH Macro GBP (BHMG), JPMorgan Emerging Markets (JMG), and Aberforth Smaller Companies Trust (ASL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does International Biotechnology compare to Ashmore Group?

Ashmore Group (LON:ASHM) and International Biotechnology (LON:IBT) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Ashmore Group has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Ashmore Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ashmore Group£144.30M9.54£94.67M£16.5412.81
International Biotechnology£78.01M4.44£37.91M£241.734.53

Ashmore Group pays an annual dividend of GBX 16.90 per share and has a dividend yield of 8.0%. International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. Ashmore Group pays out 102.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. International Biotechnology pays out 13.2% of its earnings in the form of a dividend.

39.9% of Ashmore Group shares are owned by institutional investors. Comparatively, 6.7% of International Biotechnology shares are owned by institutional investors. 37.5% of Ashmore Group shares are owned by insiders. Comparatively, 1.1% of International Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ashmore Group has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.461, suggesting that its stock price is 54% less volatile than the broader market.

Ashmore Group currently has a consensus price target of GBX 212.50, suggesting a potential upside of 0.33%. Given Ashmore Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Ashmore Group is more favorable than International Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ashmore Group
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
International Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

International Biotechnology has a net margin of 82.27% compared to Ashmore Group's net margin of 73.84%. International Biotechnology's return on equity of 27.35% beat Ashmore Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Ashmore Group73.84% 13.19% 4.52%
International Biotechnology 82.27%27.35%3.57%

In the previous week, Ashmore Group had 4 more articles in the media than International Biotechnology. MarketBeat recorded 4 mentions for Ashmore Group and 0 mentions for International Biotechnology. International Biotechnology's average media sentiment score of 0.75 beat Ashmore Group's score of -0.08 indicating that International Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Ashmore Group Neutral
International Biotechnology Positive

Summary

Ashmore Group beats International Biotechnology on 13 of the 18 factors compared between the two stocks.

How does International Biotechnology compare to The Bankers Investment Trust?

The Bankers Investment Trust (LON:BNKR) and International Biotechnology (LON:IBT) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

In the previous week, The Bankers Investment Trust had 1 more articles in the media than International Biotechnology. MarketBeat recorded 1 mentions for The Bankers Investment Trust and 0 mentions for International Biotechnology. The Bankers Investment Trust's average media sentiment score of 1.13 beat International Biotechnology's score of 0.75 indicating that The Bankers Investment Trust is being referred to more favorably in the media.

Company Overall Sentiment
The Bankers Investment Trust Positive
International Biotechnology Positive

0.5% of The Bankers Investment Trust shares are owned by institutional investors. Comparatively, 6.7% of International Biotechnology shares are owned by institutional investors. 0.0% of The Bankers Investment Trust shares are owned by insiders. Comparatively, 1.1% of International Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

The Bankers Investment Trust pays an annual dividend of GBX 2.77 per share and has a dividend yield of 1.8%. International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. The Bankers Investment Trust pays out 9.2% of its earnings in the form of a dividend. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

The Bankers Investment Trust has a beta of 0.613, meaning that its share price is 39% less volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.461, meaning that its share price is 54% less volatile than the broader market.

The Bankers Investment Trust has a net margin of 1,132.30% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat The Bankers Investment Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
The Bankers Investment Trust1,132.30% 22.55% 6.13%
International Biotechnology 82.27%27.35%3.57%

The Bankers Investment Trust has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than The Bankers Investment Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Bankers Investment Trust£322.40M4.32£218.53M£30.135.06
International Biotechnology£78.01M4.44£37.91M£241.734.53

Summary

The Bankers Investment Trust beats International Biotechnology on 9 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to BH Macro GBP?

International Biotechnology (LON:IBT) and BH Macro GBP (LON:BHMG) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

International Biotechnology has a net margin of 82.27% compared to BH Macro GBP's net margin of 54.44%. International Biotechnology's return on equity of 27.35% beat BH Macro GBP's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
BH Macro GBP 54.44%7.42%-0.31%

In the previous week, International Biotechnology's average media sentiment score of 0.75 beat BH Macro GBP's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
International Biotechnology Positive
BH Macro GBP Neutral

International Biotechnology has a beta of 0.461, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, BH Macro GBP has a beta of 0.126, suggesting that its stock price is 87% less volatile than the broader market.

6.7% of International Biotechnology shares are owned by institutional investors. Comparatively, 1.6% of BH Macro GBP shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by insiders. Comparatively, 0.1% of BH Macro GBP shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BH Macro GBP has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than BH Macro GBP, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.44£37.91M£241.734.53
BH Macro GBP£277.60M4.79£53.77M£45.689.01

Summary

International Biotechnology beats BH Macro GBP on 8 of the 12 factors compared between the two stocks.

How does International Biotechnology compare to JPMorgan Emerging Markets?

International Biotechnology (LON:IBT) and JPMorgan Emerging Markets (LON:JMG) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

JPMorgan Emerging Markets has a net margin of 95.26% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat JPMorgan Emerging Markets' return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
JPMorgan Emerging Markets 95.26%19.61%1.55%

6.7% of International Biotechnology shares are owned by institutional investors. Comparatively, 14.8% of JPMorgan Emerging Markets shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by insiders. Comparatively, 0.0% of JPMorgan Emerging Markets shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, JPMorgan Emerging Markets had 1 more articles in the media than International Biotechnology. MarketBeat recorded 1 mentions for JPMorgan Emerging Markets and 0 mentions for International Biotechnology. International Biotechnology's average media sentiment score of 0.75 beat JPMorgan Emerging Markets' score of 0.00 indicating that International Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
International Biotechnology Positive
JPMorgan Emerging Markets Neutral

International Biotechnology has a beta of 0.461, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, JPMorgan Emerging Markets has a beta of 0.906, suggesting that its stock price is 9% less volatile than the broader market.

JPMorgan Emerging Markets has lower revenue, but higher earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than JPMorgan Emerging Markets, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.44£37.91M£241.734.53
JPMorgan Emerging Markets£56.31M23.64£80.10M£4.6329.33

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. JPMorgan Emerging Markets pays an annual dividend of GBX 1.95 per share and has a dividend yield of 1.4%. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. JPMorgan Emerging Markets pays out 42.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

International Biotechnology beats JPMorgan Emerging Markets on 8 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to Aberforth Smaller Companies Trust?

International Biotechnology (LON:IBT) and Aberforth Smaller Companies Trust (LON:ASL) are both small-cap finance companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Aberforth Smaller Companies Trust has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Aberforth Smaller Companies Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.44£37.91M£241.734.53
Aberforth Smaller Companies Trust£94.68M14.16£255.01M£115.7815.15

International Biotechnology has a beta of 0.461, meaning that its share price is 54% less volatile than the broader market. Comparatively, Aberforth Smaller Companies Trust has a beta of 1.433, meaning that its share price is 43% more volatile than the broader market.

International Biotechnology has a net margin of 82.27% compared to Aberforth Smaller Companies Trust's net margin of 63.47%. International Biotechnology's return on equity of 27.35% beat Aberforth Smaller Companies Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
Aberforth Smaller Companies Trust 63.47%6.52%11.67%

In the previous week, Aberforth Smaller Companies Trust's average media sentiment score of 1.38 beat International Biotechnology's score of 0.75 indicating that Aberforth Smaller Companies Trust is being referred to more favorably in the news media.

Company Overall Sentiment
International Biotechnology Positive
Aberforth Smaller Companies Trust Positive

6.7% of International Biotechnology shares are owned by institutional investors. Comparatively, 13.1% of Aberforth Smaller Companies Trust shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by insiders. Comparatively, 0.4% of Aberforth Smaller Companies Trust shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. Aberforth Smaller Companies Trust pays an annual dividend of GBX 46.80 per share and has a dividend yield of 2.7%. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Aberforth Smaller Companies Trust pays out 40.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Aberforth Smaller Companies Trust beats International Biotechnology on 8 of the 14 factors compared between the two stocks.

Get International Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBT vs. The Competition

Export
MetricInternational BiotechnologyCapital Markets IndustryFinance SectorLON Exchange
Market Cap£349.76M£5.31B£13.71B£2.89B
Dividend Yield2.83%7.49%5.95%6.22%
P/E Ratio4.5329.3524.95366.50
Price / Sales4.441,212.46509.1690,069.18
Price / Cash155.7447.8746.1227.89
Price / Book1.433.502.706.39
Net Income£37.91M£417.39M£1.32B£5.89B
7 Day Performance-0.45%-0.27%-0.74%0.09%
1 Month Performance-3.10%-2.50%-2.19%5.99%
1 Year Performance48.37%4.86%9.05%19.42%

International Biotechnology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBT
International Biotechnology
N/AGBX 1,095
-0.9%		N/A+47.2%£349.76M£78.01M4.53N/A
ASHM
Ashmore Group
1.1907 of 5 stars		GBX 215.40
+0.7%		GBX 212.50
-1.3%		+22.7%£1.39B£144.30M13.02272
BNKR
The Bankers Investment Trust
N/AGBX 149.40
-1.1%		N/A+18.1%£1.37B£322.40M4.96N/A
BHMG
BH Macro GBP
N/AGBX 421
flat		N/A+5.2%£1.34B£277.60M9.22N/A
JMG
JPMorgan Emerging Markets
N/AGBX 135.80
-0.9%		N/A+5.6%£1.33B£56.31M29.33N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IBT) was last updated on 9/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel